样式: 排序: IF: - GO 导出 标记为已读
-
Ultrasound-Assisted Catheter-Directed Thrombolysis for the Management of Pulmonary Embolism: A Single Center Experience in a Community Hospital J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2024-03-14 Jasmine Ventenilla, Todd Rushing, Becky Ngu, David Shavelle, Neepa Rai
Current guidelines recommend anticoagulation alone for low-risk pulmonary embolism (PE) with the addition of systemic thrombolysis for high-risk PE. However, treatment recommendations for intermediate-risk PE are not well-defined. Due to bleeding risks associated with systemic thrombolysis, ultrasound-assisted catheter-directed thrombolysis (USAT) has evolved as a promising treatment modality. USAT
-
-
Sotatercept for Pulmonary Arterial Hypertension in the Inpatient Setting J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2024-02-16 Heather Torbic, Adriano R. Tonelli
Patients with pulmonary arterial hypertension (PAH) who are admitted to the hospital pose a challenge to the multidisciplinary healthcare team due to the complexity of the pathophysiology of their disease state and PAH-specific medication considerations. Pulmonary arterial hypertension is a progressive disease that may lead to death as a result of right ventricular (RV) failure. During acute on chronic
-
Effects of Patiromer and Sodium Zirconium Cyclosilicate on Blood Pressure in Rats with Chronic Kidney Disease J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2024-02-05 Lingyun Li, Jeff Budden, Carol Moreno Quinn, David Bushinsky
BackgroundPotassium-binders patiromer and sodium zirconium cyclosilicate (SZC) are approved to treat hyperkalaemia, which is frequently observed in chronic kidney disease (CKD). Elevated blood pressure (BP) is common in CKD, due in part to impaired sodium excretion. The effect of patiromer, which exchanges calcium for potassium and SZC, which exchanges sodium or hydrogen for potassium, on BP was assessed
-
Electric Cardioversion in Older Adults. Is Sedation Using Propofol Safe in the Absence of the Direct Anesthetist's Assistance? J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2024-01-31 Jarosław Karwowski, Karol Wrzosek, Jerzy Rekosz, Katarzyna Tymoszuk, Anna Wiktorska, Katarzyna Szmarowska, Mateusz Solecki, Mirosław Dłużniewski
Aims: This study aimed to assess the safety of electric cardioversion in the absence of anesthetists assistance. We also evaluated the efficacy and safety of this procedure in older adults (≥80 years) compared to younger populations. Methods: We retrospectively analyzed the data of patients who underwent electric cardioversion at our cardiology department. Patients were divided into 2 groups according
-
Assessment of Dofetilide or Sotalol Tolerability in the Elderly J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2024-01-23 Nikitha Yagnala, Lindsay Moreland-Head, Joseph J Zieminski, Kristin Mara, Shea Macielak
Background: Dofetilide and sotalol are potassium channel antagonists that require inpatient QTc monitoring during initiation, due to increased risk of fatal arrhythmias. Elderly patients are especially subject to an increased risk of fatal arrhythmias due to polypharmacy, comorbidities, and physiologic cardiac changes with aging. This study will describe the tolerability and risk factors associated
-
Prognostic Implications of Immature Platelet Fraction at 5-Year Follow-up Among ACS Patients Treated With Dual Antiplatelet Therapy J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2024-01-10 Karolina Gumiężna, Piotr Baruś, Grażyna Sygitowicz, Agnieszka Wiśniewska, Adrian Bednarek, Jakub Zabłocki, Adam Piasecki, Dominika Klimczak-Tomaniak, Janusz Kochman, Marcin Grabowski, Mariusz Tomaniak
Objective: Platelets are strongly associated with cardiovascular events due to their role in thrombotic processes. Reticulated platelets have higher prothrombotic potential. The aim of the study was to evaluate the effectiveness of immature platelet fraction (IPF) in predicting long-term clinical outcomes in patients with acute coronary syndrome (ACS). Methods: This prospective, observational study
-
Endovascular Therapies Using Catheter-Based Thrombectomy or Catheter-Directed Thrombolysis for Acute Non-Cancer Associated Inferior Vena Cava Thrombosis: A Retrospective Cohort Study J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2023-05-02 Maofeng Gong, Qing Zhao, Rui Jiang, Zhengli Liu, Boxiang Zhao, Jie Kong, Xu He, Jianping Gu
Objective:To investigate the safety and effectiveness of catheter-based therapy (CBT) compared to conventional catheter-directed thrombosis (CDT) for non-oncological patients with inferior vena cav...
-
Development of a Nomogram That Predicts the Risk of Coronary Heart Disease in Patients With Hyperlipidemia J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2023-04-25 Yuanyuan Zeng, Jing Zhao, Jingfang Zhang, Tingting Yao, Jieqiong Weng, Mengfei Yuan, Xiaoxu Shen
Background:Hyperlipidemia is one of the independent risk factors for the onset of coronary heart disease (CHD), and our aim is to construct a coronary risk prediction model for patients with hyperl...
-
Management of Heart Failure in Patients With Diabetes Mellitus in the UAE: A Call to Action J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2023-04-17 Hani Sabbour, Aftab Ahmad
Background:Heart failure (HF) is an important adverse outcome of diabetes mellitus (DM) with high rates of mortality and HF-related hospitalizations. The risk of HF is 2 times higher in patients wi...
-
High-Fructose Diet Induces Cardiac Dysfunction via Macrophage Recruitment in Adult Mice J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2023-03-30 Xiao Wang, Zuqing Xu, Rong Chang, Changchun Zeng, Yanli Zhao
Cardiovascular diseases are the leading cause of death globally, including cardiac fibrosis, myocardial infarction, cardiac hypertrophy, and heart failure. High fat/ fructose induces metabolic synd...
-
Effect of Pre-Meal Metformin With or Without an Acute Exercise Bout on Postprandial Lipemic and Glycemic Responses in Metabolic Syndrome Patients: A Randomized, Open Label, Crossover Study J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2023-02-20 Jabeur Methnani, Marwa Hajbelgacem, Taieb Ach, Faten Chaieb, Sana Sellami, Ali Bouslama, Monia Zaouali, Asma Omezzine, Ezdine Bouhlel
Introduction:Both exercise and pre-meal metformin could lower postprandial glucose and lipid profiles.Aims:To explore whether pre-meal metformin administration is superior to metformin administrati...
-
Effects of Electronic Cigarette Exposure on Myocardial Infarction and No-Reflow, and Cardiac Function in a Rat Model J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2023-02-17 Wangde Dai, Jianru Shi, Prabha Siddarth, Lifu Zhao, Juan Carreno, Michael T. Kleinman, David A. Herman, Rebecca J. Arechavala, Samantha Renusch, Irene Hasen, Amanda Ting, Robert A. Kloner
Purpose:We investigated the effects of exposure to electronic cigarettes (E-cig) vapor on the sizes of the no-reflow and myocardial infarction regions, and cardiovascular function compared to expos...
-
Epicardial Adipose Tissue and Diabetic Cardiomyopathy J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2023-02-08 Xueyuan Yang, Chao Feng, Jinping Feng
Diabetes is a long-term chronic disease, and cardiovascular disease is the leading cause of death. Diabetic cardiomyopathy (DCM), one of the cardiovascular complications of diabetes, has many uncer...
-
Fondaparinux Sodium: Recent Advances in the Management of Thrombosis J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2023-01-03 Rupert M. Bauersachs
Fondaparinux sodium is a chemically synthesized selective factor Xa inhibitor approved for the prevention and treatment of venous thromboembolic events, that is, deep vein thrombosis, pulmonary emb...
-
Up-Titration of Sacubitril/Valsartan Among Patients With Heart Failure and Preserved Ejection Fraction J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2023-01-03 Koichiro Matsumura, Takeshi Ijichi, Junko Morimoto, Kensuke Takabayashi, Mitsunori Miho, Keisuke Ueno, Eijiro Yagi, Toru Takase, Masafumi Ueno, Gaku Nakazawa
Aims:In recent large trials, sacubitril/valsartan demonstrated favorable effects in patients with HF. However, many patients do not achieve the target dose of treatment. This study investigated the...
-
Effects of Renin-Angiotensin System Inhibitors on Atrial Mechanics Parameters in Patients with Metabolic Syndrome. J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2023-01-01 Juan A Peraza-Zaldivar,Juan M Ponce-Guarneros,Ernesto G Cardona-Muñoz,Yussef Esparza-Guerrero,Ana M Saldaña-Cruz,Sergio A González-Vazquez,Laura Gonzalez-Lopez,Jorge I Gamez-Nava,Norma A Rodriguez-Jimenez
INTRODUCTION Metabolic syndrome (MS) is associated with abnormalities in atrial mechanics, atrial remodeling, and an increased risk of heart rhythm disorders. One of the most commonly used approaches to the prevention of cardiac remodeling in arterial hypertension is the administration of renin-angiotensin system (RAS) inhibitors. Therefore, this study aimed to investigate the effects of RAS inhibitors
-
Upregulation of ATP-Sensitive Potassium Channels as the Potential Mechanism of Cardioprotection and Vasorelaxation Under the Action of Pyridoxal-5-Phosphate in Old Rats. J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2023-01-01 Ruslan B Strutynskyi,Nataliіa A Strutynska,Oksana O Piven,Lidiia A Mys,Yulia V Goshovska,Raisa A Fedichkina,Iryna Y Okhai,Vladyslav R Strutynskyi,Victor E Dosenko,Pawel Dobrzyn,Vadim F Sagach
Background: The aging process is accompanied by the weakening of the protective systems of the organism, in particular by the decrease in the expression of ATP-sensitive potassium (KATP) channels and in the synthesis of H2S. The aim of our work was to investigate the role of KATP channels in the cardioprotection induced by pyridoxal-5-phosphate (PLP) in aging. Methods: Experiments were performed on
-
The Clinical Implementation of CYP2C19 Genotyping in Patients with an Acute Coronary Syndrome: Insights From the FORCE-ACS Registry. J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2023-01-01 Jaouad Azzahhafi,Wout W A van den Broek,Dean R P P Chan Pin Yin,Ankie M Harmsze,Ron H N van Schaik,Jurriën M Ten Berg
BACKGROUND Guidelines recommend prasugrel or ticagrelor for acute coronary syndrome (ACS) patients. However, these P2Y12 inhibitors increase bleeding risk compared to clopidogrel. Although genotype-guided P2Y12-inhibitor selection has been shown to reduce bleeding risk, data on its clinical implementation is lacking. METHODS The study included ACS patients receiving genotype-guided antiplatelet therapy
-
Evidence-based Management of Major Bleeding in Patients Receiving Direct Oral Anticoagulants: An Updated Narrative Review on the Role of Specific Reversal Agents. J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2023-01-01 Zohair Al Aseri,Farjah H AlGahtani,Majid F Bakheet,Ahmed H Al-Jedai,Sarah Almubrik
The indications of direct oral anticoagulants (DOACs) have expanded over the past 15 years. DOACs are effective and safe oral anticoagulants associated with lower bleeding risks and mortality than vitamin K antagonists. However, DOAC users are prone to a considerable bleeding risk, which can occur at critical sites or lead to severe life-threatening conditions. Recent statistics indicated that major
-
Efficacy and Safety of a Single-Pill Triple Combination of Olmesartan, Amlodipine, and Rosuvastatin in Hypertensive Patients with Low-to-Moderate Cardiovascular Risk: A Multicenter, Randomized, Open-Label, Active-Control, Phase IV Clinical Trial. J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2023-01-01 Byung Jin Kim,Kwang Soo Cha,Wook Hyun Cho,Eung Ju Kim,Seung-Hyuk Choi,Moo Hyun Kim,Sang-Hyun Kim,Jun-Bean Park,Seong-Mi Park,Il Suk Sohn,Kyu Hyung Ryu,In-Ho Chae
INTRODUCTION This study evaluated the efficacy and safety of a single-pill triple-combination of olmesartan/amlodipine/rosuvastatin (Olme/Amlo/Rosu) in comparison with a single-pill dual-combination of olmesartan/amlodipine (Olme/Amlo) in hypertensive patients with low-to-moderate cardiovascular risk. METHODS This multicenter, active-control, randomized study included 106 hypertensive patients at low-to-moderate
-
Residual Atherosclerotic Cardiovascular Disease Risk: Focus on Non-High-Density Lipoprotein Cholesterol. J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2023-01-01 Yonghong Luo,Daoquan Peng
Cardiovascular disease (CVD) caused by atherosclerosis is the leading cause of death worldwide. The level of low-density lipoprotein cholesterol (LDL-C), considered as the initiator of atherosclerosis, is the most widely used predictor for CVD risk and LDL-C has been the primary target for lipid-lowering therapies. However, residual CVD risk remains high even with very low levels of LDL-C. This residual
-
ARNI Versus Perindopril for Remodeling in HFrEF. A Cohort Study. J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2023-01-01 Noor Muhammad Azlan Shah Bin Atan,Mohd Firdaus Bin Hadi,Victoria Wen Yeng Teoh,Mahmoud Danaee,Alexander Loch
Introduction: Ventricular remodeling is a mal-adaptive process. Both angiotensin-converting enzyme inhibitors and sacubitril/valsartan have been shown to reverse remodeling in mostly uncontrolled observational studies. There is a lack of head-to-head studies. Methods: This cohort study compares the remodeling effects of angiotensin receptor blockers combined with a neprilysin inhibitor (ARNI) and perindopril
-
Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i): Current Evidence for Expanding the Paradigm? J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2023-01-01 Rosaria Vincenza Giglio,Emir M Muzurović,Angelo Maria Patti,Peter P Toth,Manyoo A Agarwal,Wael Almahmeed,Aleksandra Klisic,Marcello Ciaccio,Manfredi Rizzo
Background: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are low-density lipoprotein cholesterol (LDL-C)-lowering drugs that play a critical role in lipoprotein clearance and metabolism. PCSK9i are used in patients with familial hypercholesterolemia and for the secondary prevention of acute cardiovascular events in patients with atherosclerotic cardiovascular disease (CVD). Methods:
-
Effect of Esmolol on Clinical Outcomes in Critically Ill Patients: Data from the MIMIC-IV Database. J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2023-01-01 Qihong Liang,Lulan Li,Kerong Chen,Sheng An,Zhiya Deng,Jiaxin Li,Shiyu Zhou,Zhongqing Chen,Zhenhua Zeng,Shengli An
BACKGROUND AND AIMS Esmolol is a common short-acting drug to control ventricular rate. This study aimed to evaluate the association between use of esmolol and mortality in critically ill patients. METHODS This is a retrospective cohort study from MIMIC-IV database containing adult patients with a heart rate of over 100 beats/min during the intensive care unit (ICU) stay. Multivariable Cox proportional
-
Vericiguat reduces electrical and structural remodeling in a rabbit model of atrial fibrillation. J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2023-01-01 Qi Lou,Luyifei Li,Guangzhong Liu,Tiankai Li,Li Zhang,Yanxiang Zang,Chengchuang Zhan,Hong Wang,Weimin Li
Purpose: The molecular etiology of atrial fibrillation (AF) and its treatment are poorly understood. AF involves both electrical and structural features. Vericiguat can ameliorate cardiac remodeling in heart failure. The effects of vericiguat on AF, however, are unclear. Here, the actions of vericiguat on atrial structural and electrical remodeling in AF and its possible mechanisms were investigated
-
The Prognostic Value of the Triglyceride Glucose Index in Patients With Acute Myocardial Infarction. J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2023-01-01 Qian Hao,Zhao Yuanyuan,Chen Lijuan
Objective: The triglyceride-glucose (TyG) index is a simple and reliable surrogate for insulin resistance. Recent studies have suggested that the TyG index is an independent predictor of cardiovascular disease. However, the prognostic value of the TyG index in patients with acute myocardial infarction (AMI) remains uncertain. Thus, this study aimed to evaluate the prognostic value of the TyG index
-
Protective Effect of Nicorandil on Contrast-Induced Acute Kidney Injury After Emergency Percutaneous Coronary Intervention. J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2023-01-01 Zuo-Zhong Yu,Zheng-Xiong Xu,Yue-Hua Ruan,Long-Long Hu,Ming-Hua Wen,Tie-Qiu Huang,Zhi-Gang You,Yan-Qing Wu,Ren-Qiang Yang
Objective: To investigate the protective effect of nicorandil on contrast-induced acute kidney injury (CIAKI) in patients with acute ST-segment elevation myocardial infarction (STEMI) after emergency percutaneous coronary intervention (PCI). Methods: This is a single-center, retrospective control study. A total of 156 patients with STEMI were divided into the nicorandil group (n = 55) and the control
-
Cardioprotection and its Translation: A Need for New Paradigms? Or for New Pragmatism? An Opinionated Retro- and Perspective. J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2023-01-01 Gerd Heusch
The dawn of cardioprotection by infarct size reduction originated from the idea to favourably alter the oxygen demand-supply balance of the ischaemic/infarcting myocardium by reducing the contractile determinants of its oxygen consumption. This idea is probably not correct, since the ischaemic/infarcting myocardium does not contract anyway. None of the successful initial preclinical attempts of infarct
-
Evolocumab is Initiated in Central and Eastern Europe at Much Higher LDL-C Levels Than Recommended in Guidelines: Results from the Observational HEYMANS Study. J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2023-01-01 Vladimír Blaha,Roman Margoczy,Ivo Petrov,Arman Postadzhiyan,Katarína Rašlová,Hana Rosolová,Ian Bridges,Nafeesa N Dhalwani,Marie Zachlederova,Kausik K Ray
Purpose: We examined clinical characteristics and low-density lipoprotein cholesterol (LDL-C) lowering in patients initiating evolocumab in real-world practice in a Central and Eastern European (CEE) cohort from the pan-European HEYMANS study. Methods: Patients from Bulgaria, Czech Republic, and Slovakia were enrolled at initiation of evolocumab (baseline) as per local reimbursement criteria. Demographic/clinical
-
Ticagrelor Loading on ST-Elevation Myocardial Infarction: Interaction With Prodromal Angina on Infarct Size and Clinical Events. J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2023-01-01 João Pedro Faria,Pedro Oliveira,André Alexandre,David Sá Couto,Ricardo Costa,Andreia Campinas,André Frias,Bruno Brochado,Raquel Santos,João Silveira,Severo Torres,André Luz
INTRODUCTION Ticagrelor might reduce infarct size by exerting a more potent antiplatelet effect or by promoting a potential conditioning stimulus in ST-elevation myocardial infarction (STEMI) patients. Pre-infarction angina (PIA) is an effective preconditioning stimulus that reduces ischemia-reperfusion injury. Because little is known on the interaction of PIA in STEMI-patients loaded with ticagrelor
-
Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2022-12-22 Emir M. Muzurović, Špela Volčanšek, Karin Zibar Tomšić, Andrej Janež, Dimitri P. Mikhailidis, Manfredi Rizzo, Christos S. Mantzoros
The obesity pandemic is accompanied by increased risk of developing metabolic syndrome (MetS) and related conditions: non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH),...
-
Antiplatelet Therapy and Bleeding Outcomes With CYP2C19 Genotyping J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2022-12-12 James C. Coons, James M. Stevenson, Ami Patel, A. J. Conrad Smith, Linda Prebehalla, Philip E. Empey
Purpose:The impact of antiplatelet therapy with availability of CYP2C19 genotyping on bleeding in a real-world setting has not been extensively studied.Methods:Prospective, single-center, cohort st...
-
Prescribing Patterns of Direct-Acting Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Retrospective Cohort Analysis J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2022-12-06 Jorge L. Reyes, Charles A. Herzog, Heng Yan, Nicholas S. Roetker, James B. Wetmore
Background:The association of patient and prescriber characteristics with use of warfarin versus direct-acting oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) and chronic kidn...
-
A Phase 3 Randomized Controlled Trial to Evaluate Efficacy and Safety of New-Formulation Zenon (Rosuvastatin/Ezetimibe Fixed-Dose Combination) in Primary Hypercholesterolemia Inadequately Controlled by Statins J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2022-11-24 Alberico L. Catapano, Michal Vrablik, Yuri Karpov, Baptiste Berthou, Megan Loy, Marie Baccara-Dinet
Objective:In primary hypercholesterolemia many people treated with statins do not reach their plasma LDL-C goals and are at increased risk of cardiovascular disease (CVD). This study aimed to evalu...
-
Association of Valproic Acid Use With Post-Myocardial Infarction Heart Failure Development: A Meta-Analysis of Two Retrospective Case–Control Studies J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2022-11-23 Joseph D. English, Shuo Tian, Zhong Wang, Jasmine A. Luzum
Background:Despite advances in treatments, myocardial infarction (MI) remains a significant cause of morbidity and mortality worldwide. Our team has previously shown that valproic acid (VPA) is car...
-
Direct Ischemic Postconditioning After Carotid Endarterectomy in the Prevention of Postoperative Cerebral Ischemic Complications—Observational Case–Control Study J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2022-11-15 Nenad Ilijevski, Igor Atanasijević, Branko Lozuk, Predrag Gajin, Predrag Matić, Srđan Babić, Dragan Sagić, Dragana Unić-Stojanović, Slobodan Tanasković
Introduction:Ischemic postconditioning (IPCT) represents one of the several therapeutic strategies to attenuate ischemic reperfusion injury (IR) after carotid endarterectomy (CEA). We here present ...
-
Evaluation of Risk Factors Associated With Antihypertensive Treatment Success Employing Data Mining Techniques J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2022-11-02 Selçuk Şen, Denizhan Demirkol, Mert Kaşkal, Murat Gezer, Ayşenur Yaman Bucak, Nermin Gürel, Yasemin Selalmaz, Çiğdem Erol, Ali Yağız Üresin
Objective:This study aimed to evaluate the effects of potential risk factors on antihypertensive treatment success.Methods:Patients with hypertension who were treated with antihypertensive medicati...
-
Randomized Clinical and Biochemical Study Comparing the Effect of L-arginine and Sildenafil in Beta Thalassemia Major Children With High Tricuspid Regurgitant Jet Velocity J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2022-10-25 Eman El-Khateeb, Sahar Mohamed El-Haggar, Osama El-Razaky, Mohamed Ramadan El-Shanshory, Tarek Mohamed Mostafa
Background:Pulmonary hypertension (PHT) is common in β-thalassemia patients due to hemolysis, iron overload and diminished nitric oxide (NO) levels. Biochemical markers can help to understand the p...
-
CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2022-10-25 C. Michael Gibson, Syed Hassan A. Kazmi, Serge Korjian, Gerald Chi, Adam T. Phillips, Sahar Memar Montazerin, Danielle Duffy, Bo Zheng, Mark Heise, Charles Liss, Lawrence I. Deckelbaum, Samuel D. Wright, Andreas Gille
Introduction:Cholesterol efflux capacity (CEC) is impaired following acute myocardial infarction (AMI). CSL112 is an intravenous preparation of human plasma-derived apoA-I formulated with phosphati...
-
Impact of COVID-19 on the Prescribing Pattern of Oral Anticoagulants for Atrial Fibrillation After Cardiac Surgery J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2022-10-02 Dannick Brochu, Amélie St-Arnaud, Louis-Étienne Marchand, Pierre Voisine, Julie Méthot
Background:Because of logistic challenges associated with the COVID-19 pandemic, direct oral anticoagulants (DOAC) were favored over warfarin in patients presenting postoperative atrial fibrillatio...
-
Understanding the Mechanism of Drug Transfer and Retention of Drug-Coated Balloons J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2022-08-16 Estefanny Villar-Matamoros, Lauren Stokes, Alyssa Lloret, Meagan Todd, Bryan W. Tillman, Saami K. Yazdani
Objective:The purpose of this study was to determine the impact of varying inflation parameters on paclitaxel delivery and retention using a commercially available DCB.Background:Drug-coated balloo...
-
Morphine Use in ST-Elevation Myocardial Infarction With Downstream P2Y12 Receptor Blockers—Insight From Observational Study J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2022-07-21 Ariel Roguin, Ofer Kobo, Simcha Ron Meisel, Emad Maraga, Aaron Frimerman, Naama Amsalem, Rinat Malka, Yaniv Levi, Rami Abu Fanne
Background and Aims:Morphine use for patients presenting with NSTE-ACS is associated with excess mortality. However, the role of morphine in STE-ACS is ill characterized. We have recently confirmed...
-
Duration of Heart Failure With Reduced Ejection Fraction Associated With Electrocardiographic Outcomes Before and After Sacubitril/Valsartan J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2022-06-17 Po-Lin Lin, Ying-Hsiang Lee, Lawrence Yu-Min Liu, Cheng-Ting Tsai, Ten-Fang Yang, Wei-Ru Chiou, Mu-Yang Hsieh, Hung-Yu Chang, Chun-Che Huang
Aim:Changes in QRS duration in patients with heart failure with reduced ejection fraction (HFrEF) after sacubitril/valsartan therapy is not fully understood. This study aimed to assess the associat...
-
Renin-Angiotensin-Aldosterone System Inhibitors, Statins, and Beta-Blockers in Diabetic Patients With Critical Limb Ischemia and Foot Lesions J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2022-05-20 Paolo Cimaglia, Davide Bernucci, Laura Sofia Cardelli, Anna Carone, Giuseppe Scavone, Marco Manfrini, Stefano Censi, Simone Calvi, Roberto Ferrari, Gianluca Campo, Luca Dalla Paola
Medical therapy for secondary prevention is known to be under-used in patients with peripheral artery disease (PAD). Few data are available on the subgroup with critical limb ischemia (CLI). Prescr...
-
A Comprehensive Review of PCSK9 Inhibitors J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2022-05-20 Caroline Coppinger, Mohammad Reza Movahed, Veronica Azemawah, Lee Peyton, James Gregory, Mehrnoosh Hashemzadeh
Cardiovascular disease (CVD) is the leading cause of death in the United States and worldwide. A major risk factor for this condition is increased serum low-density lipoprotein cholesterol (LDL-C) ...
-
Continuation Versus Interruption of Renin-Angiotensin System Inhibitors in Acute Decompensated Heart Failure: A Brief Report J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2022-05-11 Christian A. Bernhardi, Stephen Fendt, Brent N. Reed, Gautam Ramani, Stormi E. Gale
This article is temporarily under embargo.
-
Bioassays of Humoral Cardioprotective Factors Released by Remote Ischemic Conditioning in Patients Undergoing Coronary Artery Bypass Surgery J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2022-05-05 Helmut Raphael Lieder, Pia Tüller, Felix Braczko, Afsaneh Zandi, Markus Kamler, Matthias Thielmann, Gerd Heusch, Petra Kleinbongard
Remote ischemic conditioning (RIC) induces the release of circulating cardioprotective factors and attenuates myocardial ischemia/reperfusion injury. Evidence for such humoral cardioprotective fact...
-
Platelet-to-Lymphocyte Ratio as Marker of Platelet Activation in Patients on Potent P2Y12 Inhibitors J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2022-04-28 Patricia P. Wadowski, Joseph Pultar, Constantin Weikert, Beate Eichelberger, Maximilian Tscharre, Renate Koppensteiner, Simon Panzer, Thomas Gremmel
A high platelet-to-lymphocyte ratio (PLR) has recently been associated with ischemic outcomes in cardiovascular disease. Increased platelet reactivity and leukocyte-platelet aggregate formation are...
-
Association of Cardiovascular Disease and Military Veteran Status With Impairments in Physical and Psychological Functioning: Retrospective Cross-Sectional Analysis of US National Survey Data J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2022-04-04 Nicole K. Early, Kelsey Buckley, Nana Entsuah, Kathleen A. Fairman
Introduction:The Veterans Health Administration (VHA) provides multidisciplinary team-based care with peer-to-peer support for diabetes and obesity, but not for most heart diseases.Objective:To inf...
-
A Long-Term Study Evaluating the Effects of Nicorandil Treatment on Duchenne Muscular Dystrophy-Associated Cardiomyopathy in mdx Mice J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2022-03-30 Melanie Gartz, Margaret Haberman, Mariah J. Prom, Margaret J. Beatka, Jennifer L. Strande, Michael W. Lawlor
Background:Duchenne muscular dystrophy (DMD) is a neuromuscular disease caused by dystrophin gene mutations affecting striated muscle. Due to advances in skeletal muscle treatment, cardiomyopathy h...
-
Corrigendum to “Direct Oral Anticoagulants in the Treatment of Left Ventricular Thrombus: A Retrospective, Multicenter Study and Meta-Analysis of Existing Data” J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2022-03-22
John M. Cochran, Xiaoming Jia, Jessica Kaczmarek, Kristen A. Staggers, Mahmoud Al Rifai, Ihab R. Hamzeh, and Yochai Birnbaum. Direct oral anticoagulants in the treatment of left ventricular thrombus: a retrospective, multicenter study and meta-analysis of existing data. J Cardiovasc Pharmacol Therap 2021;26(2):173-178. DOI: 10.1177/1074248420967644
-
Nitric Oxide Is the Cause of Nitroglycerin Tolerance: Providing an Old Dog New Tricks for Acute Heart Failure J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2022-03-12 Wayne Kaesemeyer, Tatsiana Suvorava
Our paper highlights the past 50 years of research focusing solely on tolerance involving nitroglycerin (glyceryl trinitrate, GTN). It also identifies and discusses inconsistencies in previous mechanistic explanations that have failed to provide a way to administer GTN continuously, free of limitations from tolerance and without the requirement of a nitrate-free interval. We illustrate, for the first
-
Estimated Aggregate Treatment Benefit With Addition of Multiple Novel Medications for Secondary Prevention of Atherosclerotic Cardiovascular Disease J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2022-03-08 Robert W. Ariss, Rajesh Gupta
Purpose: Interest in improving residual cardiovascular (CV) risk by targeting multiple causative pathways has been growing. Several medications including icosapent ethyl, rivaroxaban, and ezetimibe have been shown to individually improve outcomes in the secondary prevention of atherosclerotic cardiovascular disease (ASCVD) beyond conventional therapy consisting of aspirin and statins. While each drug
-
Early Detection of Atrial Fibrillation in Community Pharmacies—CRIFAFARMA Study J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2022-02-24 María González Valdivieso, Domingo Orozco-Beltrán, Adriana López-Pineda, Vicente Francisco Gil-Guillén, José A. Quesada, Concepción Carratalá-Munuera, Rauf Nouni-García
Background: Atrial fibrillation (AF) is the most common arrhythmia to appear in clinical practice. People with AF have 5 times the risk of stroke compared to the general population. Objective: This study aimed to determine the prevalence of AF in people over the age of 50 without known AF, who presented to a community pharmacy to check their cardiovascular risk factors, to identify risk factors associated
-
The Association of Alanine Aminotransferase Levels With Myocardial Perfusion Imaging and Cardiovascular Morbidity J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2022-01-25 David Yardeni, Ronen Toledano, Victor Novack, Aryeh Shalev, Arik Wolak, Yaron Rotman, Ohad Etzion
Introduction: Studies suggest that non-alcoholic fatty liver disease (NAFLD) is associated with an independent risk of cardiovascular disease (CVD). We utilized a large cohort of patients undergoing myocardial perfusion imaging (MPI) with single photon emission computed tomography (SPECT) to determine the association between alanine aminotransferase (ALT) as a surrogate marker for presumed NAFLD, and
-
Thanks to Reviewers J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2022-01-20
The journal sincerely thanks the following individuals who reviewed one or more manuscripts during 2021:
-
Vorapaxar for Prevention of Major Adverse Cardiovascular and Limb Events in Peripheral Artery Disease J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2022-01-10 Justin T. Morrison, Nicholas Govsyeyev, Connie N. Hess, Marc P. Bonaca
Peripheral artery disease (PAD) is a severe manifestation of atherosclerosis. Patients with PAD are at heightened risk for atherothrombotic complications, including myocardial infarction and stroke (MACE); however, there is also an equal or greater risk of major adverse limb events (MALE), such as acute limb ischemia (ALI) and major amputation. Therefore, there is a need for effective medical therapies
-
A Review of Pulmonary Arterial Hypertension Treatment in Extracorporeal Membrane Oxygenation: A Case Series of Adult Patients J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2022-01-10 Heather Torbic, Benjamin Hohlfelder, Sudhir Krishnan, Adriano R. Tonelli
Background: Little data is published describing the use of medications prescribed for pulmonary arterial hypertension (PAH) in patients receiving extracorporeal membrane oxygenation (ECMO). Even though many patients with PAH may require ECMO as a bridge to transplant or recovery, little is reported regarding the use of PAH medications in this setting. Methods: This retrospective case series summarizes
-
Associations of Atrial Fibrillation Patterns With Mortality and Cardiovascular Events: Implications of the MISOAC-AF Trial J. Cardiovasc. Pharmacol. Ther. (IF 2.6) Pub Date : 2022-01-10 Amalia Baroutidou, Anastasios Kartas, Athanasios Samaras, Andreas S. Papazoglou, Eleni Vrana, Dimitrios V. Moysidis, Evangelos Akrivos, Anastasios Papanastasiou, Ioannis Vouloagkas, Michail Botis, Evangelos Liampas, Artemios G. Karagiannidis, Efstratios Karagiannidis, Georgios Efthimiadis, Haralambos Karvounis, Apostolos Tzikas, George Giannakoulas
Aim: This retrospective cohort study aimed to evaluate the prognostic implications of the distinct atrial fibrillation (AF) temporal patterns: first diagnosed, paroxysmal, and persistent or permanent AF. Methods: In this post hoc analysis of the MISOAC-AF trial (NCT02941978), a total of 1052 patients with AF (median age 76 years), discharged from the cardiology ward between 2015 and 2018, were analyzed